REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Trading Update and Notice of Results

1 Feb 2021 07:00

RNS Number : 4589N
BATM Advanced Communications Ld
01 February 2021
 

LEI: 213800FLQUB9J289RU66

1 February 2021

 

BATM Advanced Communications Limited

("BATM" or "the Group")

 

Trading Update and Notice of Results

 

BATM (LSE: BVC; TASE: BVC), a leading provider of real-time technologies for networking solutions and medical laboratory systems, provides the following update on trading for the year ended 31 December 2020 ahead of announcing its annual results on Monday 22 February 2021.

 

As stated in the interim results announcement, the Group entered the second half of 2020 with a substantially higher backlog than at the same point in the prior year. This momentum continued through the second half, with stronger than anticipated demand for the Group's diagnostics solutions towards the end of the year as the second wave of the COVID-19 pandemic spread across the globe. Consequently, BATM expects revenue for full year 2020 to be at least $180m - significantly ahead of the upgraded market expectations - representing annual growth of over 45% and, consequently, EBITDA to be substantially ahead of market expectations.

 

The substantial growth over the previous year was driven by the Bio-Medical division. In particular, the Diagnostics unit rapidly developed testing kits in response to the outbreak of COVID-19 and received strong demand throughout the year for its reagents and instruments. These sales were primarily to public health authorities in Europe and South East Asia, and the Group has continued to receive significant orders for its diagnostic solutions into 2021. The Eco-Med unit also contributed to the exceptional performance of the Bio-Medical division in 2020 with the manufacture of critical care ventilators.

 

The Networking & Cyber division remained resilient despite the restrictions on travel and ability to install equipment in customers' premises due to global lockdowns. In addition, the Group continued to make significant progress with its network function virtualisation ("NFV") solution - which the Group expects to become a key growth engine of the business - securing its first tier 1 customer for NFVTime with a three-year licensing agreement and conducting several successful proofs-of-concept with tier 1 operators in Europe and APAC, including Vodafone.

The Group will provide further detail in its full year results announcement.

 

Full Year Results Presentation

 

Dr Zvi Marom, Chief Executive Officer, and Moti Nagar, Chief Financial Officer, will be hosting a presentation via webinar for investors and analysts at 2.00pm GMT on Monday 22 February 2021. To register to participate, please contact clairenorbury@luther.co.uk

 

 

 

Enquiries:

 

BATM Advanced Communications

Dr Zvi Marom, Chief Executive Officer

+972 9866 2525

Moti Nagar, Chief Financial Officer

Shore Capital

Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)

Henry Willcocks (Corporate Broking)

+44 20 7408 4050 

Luther Pendragon

Harry Chathli, Claire Norbury

+44 20 7618 9100

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCFFFLILEILVIL

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.